抑制166LP17|LQVTDSGLYRCVIYHPP|cas:887255-16-5|西域试剂

抑制166LP17,LQVTDSGLYRCVIYHPP,99.78%

产品编号：西域质检-MCP3400| CAS NO：887255-16-5| 分子式：C₈₉H₁₃₇N₂₃O₂₅S| 分子量：1961.25

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
西域质检-MCP3400	￥750.00	杭州北京（现货）
西域质检-MCP3400	￥1800.00	杭州北京（现货）
西域质检-MCP3400	￥3200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

抑制166LP17

产品介绍

LQVTDSGLYRCVIYHPP (LP17) 是一种髓系细胞表达的触发受体 1 (TREM-1) 抑制肽。LQVTDSGLYRCVIYHPP 显著减轻缺血诱导的梗死和神经元损伤。LQVTDSGLYRCVIYHPP 可进入大脑，阻断 TREM-1。

生物活性

LQVTDSGLYRCVIYHPP (LP17) is a triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LQVTDSGLYRCVIYHPP substantially alleviates ischemia-induced infarction and neuronal injury. LQVTDSGLYRCVIYHPP can get access into brain and block TREM-1.

体外研究

LQVTDSGLYRCVIYHPP (LP17) (1 or 10 μM; 24 h) substantially decreases mRNA levels of pro-inflammatory cytokines and chemokines after reoxygenation and remarkably attenuates extracellular protein levels of IL-1β and IL-18 in a microglia oxygen-glucose deprivation (OGD) model.
LQVTDSGLYRCVIYHPP (LP17) (10 μM; 24 h) interacts with microglial SYK.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR

Cell Line:	Primary microglia
Concentration:	1 or 10 μM
Incubation Time:	24 h
Result:	Decreased mRNA levels of NLRP3, IL-1β, IL-18, IL-6, CD16, CD32, iNOS, MCP-1, CXCL-1, and CXCL-2 after reoxygenation.

Western Blot Analysis

Cell Line:	Primary microglia
Concentration:	10 μM
Incubation Time:	24 h
Result:	Suppressed ischemia/reperfusion-induced increments in CARD9, p-p65 in CARD9/NF-κB signaling and NLRP3, ASC, cleaved caspase-1, mature IL-1β, and mature IL-18 in NLRP3/caspase-1 signaling in a microglia oxygen-glucose deprivation (OGD) model.

体内研究
(In Vivo)

LQVTDSGLYRCVIYHPP (LP17) (0.5 or 1 mg/kg; intranasal; daily for 3 days) alleviates ischemia-induced infarction and neuronal injury in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male C57BL/6J mice (20-25 g), mice cerebral ischemia/reperfusion (I/R) model induced by middle cerebral artery occlusion (MCAO)
Dosage:	0.5 mg/kg or 1 mg/kg
Administration:	Intranasal administration, once daily for 3 consecutive days after MCAO
Result:	Abolished ischemia-induced TREM-1 elevation at 1 mg/kg. Significantly reduced infarct volume by 27.3%, induced a markedly reduction in TUNEL positive cells and FJC positive neurons at 1 mg/kg. Rescued neurological deficits and cognitive dysfunction of MCAO mice. Inhibited microglial M1 polarization and neutrophil infiltration.

体内研究

LQVTDSGLYRCVIYHPP (LP17) (0.5 or 1 mg/kg; intranasal; daily for 3 days) alleviates ischemia-induced infarction and neuronal injury in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male C57BL/6J mice (20-25 g), mice cerebral ischemia/reperfusion (I/R) model induced by middle cerebral artery occlusion (MCAO)
Dosage:	0.5 mg/kg or 1 mg/kg
Administration:	Intranasal administration, once daily for 3 consecutive days after MCAO
Result:	Abolished ischemia-induced TREM-1 elevation at 1 mg/kg. Significantly reduced infarct volume by 27.3%, induced a markedly reduction in TUNEL positive cells and FJC positive neurons at 1 mg/kg. Rescued neurological deficits and cognitive dysfunction of MCAO mice. Inhibited microglial M1 polarization and neutrophil infiltration.

体内研究

LQVTDSGLYRCVIYHPP (LP17) (0.5 or 1 mg/kg; intranasal; daily for 3 days) alleviates ischemia-induced infarction and neuronal injury in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male C57BL/6J mice (20-25 g), mice cerebral ischemia/reperfusion (I/R) model induced by middle cerebral artery occlusion (MCAO)
Dosage:	0.5 mg/kg or 1 mg/kg
Administration:	Intranasal administration, once daily for 3 consecutive days after MCAO
Result:	Abolished ischemia-induced TREM-1 elevation at 1 mg/kg. Significantly reduced infarct volume by 27.3%, induced a markedly reduction in TUNEL positive cells and FJC positive neurons at 1 mg/kg. Rescued neurological deficits and cognitive dysfunction of MCAO mice. Inhibited microglial M1 polarization and neutrophil infiltration.

性状

Solid

溶解性数据

In Vitro:

DMSO : 25 mg/mL (12.75 mM; Need ultrasonic)

H₂O : 7.69 mg/mL (3.92 mM; ultrasonic and adjust pH to 2 with HCl)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.5099 mL	2.5494 mL	5.0988 mL
5 mM	0.1020 mL	0.5099 mL	1.0198 mL
10 mM	0.0510 mL	0.2549 mL	0.5099 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light, under nitrogen